26 April 2023
EMA/PDCO/164725/2023
Human Medicines Division

Paediatric Committee (PDCO)

Minutes for the meeting on 28-31 March 2023

Chair: Brian Aylward – Vice-Chair: Sylvie Benchetrit

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Of note, this set of minutes is a working document primarily designed for PDCO members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introductions 9

1.1. Welcome and declarations of interest of members, alternates and experts 9

1.2. Adoption of agenda 9

1.3. Adoption of the minutes 9

2. Opinions 9

2.1. Opinions on Products 9

2.1.1. 2-amino-5-(carbamylamino)pentanoic acid (L-citrulline) - EMEA-002612-PIP02-22 9

2.1.2. Itolizumab - Orphan - EMEA-003208-PIP02-22 10

2.1.3. Albaconazole - EMEA-003279-PIP01-22 10

2.1.4. Opelconazole - EMEA-003249-PIP01-22 10

2.1.5. A 2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting fused in sarcoma (FUS) pre-mRNA - EMEA-003024-PIP01-21 11

2.1.6. Ocrelizumab - EMEA-000310-PIP05-22 11

2.1.7. Pembrolizumab / favezelimab - EMEA-003104-PIP02-22 11

2.1.8. Pembrolizumab / vibostolimab - EMEA-003063-PIP02-22 12

2.1.9. Aticaprant - EMEA-003251-PIP01-22 12

2.1.10. Atrasentan - Orphan - EMEA-001666-PIP02-21 13

2.1.11. Atorvastatin / ezetimibe - EMEA-003373-PIP01-22 13

2.1.12. Ramipril / indapamide - EMEA-003372-PIP01-22 13

2.1.13. Nipocalimab - Orphan - EMEA-002559-PIP07-22 14

2.1.14. Adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene (LY3884963) - Orphan - EMEA-003374-PIP01-22 14

2.1.15. 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro- 2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop- 2-en-1-one adipate - EMEA-003364-PIP02-22 14

2.1.16. N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride - Orphan - EMEA-003371-PIP01-2215

2.1.17. Palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20) / Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20) / Palmitoyl-KSS-GQAEPDRAHYNIVTF (HPV-16 E7 43-57) / Palmitoyl-KSS-KKLLMGTLGIVCPICSQKP(HPV-16 E7 82-98) / Palmitoyl-KSS-LLMGTLGIV (HPV-16 E7 82-90) /Palmitoyl-KSS-ELQTTIHDIILECVYCKQQLL (HPV-16 E6 25-45) / [(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl]-trimethylazanium chloride (R-DOTAP chloride) - EMEA-003370-PIP01-2215

2.1.18. Recombinant humanised monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1κ) directed against integrin alpha V beta 8 produced in Chinese hamster ovary (CHO) cells - EMEA-003376-PIP01-22 16

2.1.19. Pitavastatin / ezetimibe - EMEA-003390-PIP01-23 17

2.1.20. Thiocolchicoside / diclofenac - EMEA-003339-PIP02-23 17

2.1.21. Isopropyl alcohol / chlorhexidine (digluconate) - EMEA-001338-PIP02-23 18

2.2. Opinions on Compliance Check 18

2.2.1. Birch bark extract - EMEA-C-001299-PIP03-17-M01 18
2.2.2. Eltrombopag - EMEA-C-000170-PIP03-13-M04 18
2.2.3. Recombinant human A disintegrin and metalloprotease with thrombospondin type-1 motifs 13 - EMEA-C1-001160-PIP01-11-M03 18
2.2.4. Entrectinib - EMEA-C-002096-PIP01-16-M03 19
2.2.5. Larotrectinib - EMEA-C-001971-PIP02-16-M04 19
2.2.6. Crizotinib - EMEA-C-001493-PIP03-18-M01 19
2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan 20
2.3.1. Tralokinumab - EMEA-001900-PIP02-17-M07 20
2.3.2. Dasiglucagon - EMEA-002233-PIP01-17-M02 20
2.3.3. Elosulfase alfa - Orphan - EMEA-000973-PIP01-10-M04 20
2.3.4. Migalastat (hydrochloride) - Orphan - EMEA-001194-PIP01-11-M06 21
2.3.5. Romosozumab - EMEA-001075-PIP04-15-M06 21
2.3.6. Tolvaptan - EMEA-001231-PIP02-13-M10 21
2.3.7. Guselkumab - EMEA-001523-PIP04-19-M02 22
2.3.8. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP02-20-M01 22
2.3.9. Valoctocogene roxaparvovec - Orphan - EMEA-002427-PIP01-18-M02 22
2.3.10. Anifrolumab - EMEA-001435-PIP02-16-M02 23
2.3.11. Upadacitinib - EMEA-001741-PIP04-17-M04 23
2.3.12. Gepotidacin - EMEA-002443-PIP01-18-M02 23
2.3.13. Maribavir - Orphan - EMEA-000353-PIP02-16-M03 24
2.3.14. Efgartigimod alfa - Orphan - EMEA-002597-PIP05-21-M01 24
2.3.15. Lasmiditan - EMEA-002166-PIP01-17-M07 24
2.3.16. Vatiquinone - Orphan - EMEA-001238-PIP03-21-M01 25
2.3.17. Binimetinib - EMEA-001454-PIP03-15-M03 25
2.3.18. Encorafenib - EMEA-001588-PIP01-13-M03 25
2.3.19. Isatuximab - EMEA-002205-PIP01-17-M04 26
2.3.20. Repotrectinib - EMEA-002635-PIP02-21-M01 26
2.3.21. Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human α-L-iduronidase (IDUA) gene - Orphan - EMEA-003001-PIP01-21-M01 26
2.3.22. Iptacopan - Orphan - EMEA-002705-PIP01-19-M01 27
2.3.23. Meloxicam / bupivacaine - EMEA-002246-PIP01-17-M03 27
2.3.24. Benralizumab - EMEA-001214-PIP09-21-M01 28
2.3.25. Sodium chloride / idrevloride - Orphan - EMEA-002935-PIP01-20-M03 28
2.3.26. Finerenone - EMEA-001623-PIP01-14-M06 29
2.3.27. Sparsentan - Orphan - EMEA-001984-PIP02-20-M01 29
2.3.28. Cholera vaccine, recombinant, live, oral (strain CVD 103-HgR) - EMEA-001490-PIP01-13-M04 29

2.3.29. Acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid) - Orphan - EMEA-002796-PIP01-20-M01 30
2.3.30. Cariprazine hydrochloride - EMEA-001652-PIP01-14-M05 30
2.3.31. Elasomeran / imelasomeran, elasomeran / davesomeran, elasomeran - EMEA-002893-PIP01-20-M03 30
2.4. Opinions on Re-examinations 31
2.5. Opinions on Review of Granted Waivers 31
2.6. Finalisation and adoption of Opinions 31
2.7. Partial Compliance Checks completed by EMA 31
2.7.1. Lacosamide - EMEA-C2-000402-PIP03-17-M06 31
3. Discussion of applications 31
3.1. Discussions on Products D90-D60-D30 31
3.1.1. Insulin human (rDNA) - EMEA-003194-PIP02-22 31
3.1.2. Crofelemer- Orphan - EMEA-003296-PIP01-22 31
3.1.3. Efgartigimod alfa - EMEA-002597-PIP08-22 32
3.1.4. Asunercept - Orphan - EMEA-003201-PIP01-22 32
3.1.5. Fosmanogepix - Orphan - EMEA-003280-PIP01-22 32
3.1.6. RNA replicase inhibitor - EMEA-003306-PIP01-22 32
3.1.7. Humanised VHH-type bispecific antibody against complement component 5 and serum albumin - EMEA-003302-PIP01-22 32
3.1.8. Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z - EMEA-003264-PIP01-22 32
3.1.9. Live attenuated respiratory syncytial virus (RSV) - EMEA-003277-PIP01-22 33
3.1.10. Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation - EMEA-003309-PIP01-22 33
3.1.11. Upadacitinib - EMEA-001741-PIP08-22 33
3.1.12. *Escherichia coli*, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase and L-amino acid deaminase - EMEA-003381-PIP01-22 33
3.1.13. Leuprorelin - EMEA-003354-PIP01-22 33
3.1.14. Cemdisiran - Orphan - EMEA-003237-PIP02-22 33
3.1.15. Pozelimab - EMEA-003238-PIP02-22 34
3.1.16. Axatilimab - EMEA-003385-PIP01-22 34
3.1.17. Inebilizumab - EMEA-001911-PIP02-22 34
3.1.18. Cobolimab - EMEA-003273-PIP02-22 34
3.1.19. Pembrolizumab / vibostolimab - EMEA-003063-PIP03-22 34
3.1.20. Taldefgrobep alfa - EMEA-003386-PIP01-22 34
3.1.21. EMEA-003319-PIP04-22 34
3.1.22. *Neisseria meningitidis* group A, C, W, Y polysaccharide conjugated to tetanus toxoid carrier protein, and *Neisseria meningitidis* serogroup B proteins and protein-based active substance - EMEA-003379-PIP01-22 35

3.1.23. Recombinant human monoclonal antibody to insulin receptor - Orphan - EMEA-002813-PIP01-23 35
3.1.24. Inebilizumab - EMEA-001911-PIP03-23 35
3.1.25. Upadacitinib - EMEA-001741-PIP09-23 35
3.1.26. Iodine (131I) apamistamab - Orphan - EMEA-003395-PIP01-23 35
3.1.27. Haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R,4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate (ECT-001-CB) - Orphan - EMEA-003025-PIP0-23 35
3.1.28. Amphotericin B - Orphan - EMEA-003391-PIP01-23 36
3.1.29. Broadly neutralising anti-HIV human monoclonal antibody - EMEA-003392-PIP01-23 36
3.1.30. Carbidopa / levodopa - EMEA-003384-PIP02-23 36
3.1.31. Deutetrabenazine - EMEA-002052-PIP02-23 36
3.1.32. Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) - EMEA-003383-PIP02-23 36
3.1.33. Belzutifan - Orphan - EMEA-002619-PIP02-23 36
3.1.34. EMEA-003260-PIP02-23 37
3.1.35. Dordaviprone - Orphan - EMEA-003389-PIP01-23 37
3.1.36. (S)-lactic acid - EMEA-003247-PIP02-23 37
3.1.37. ALM (Almonds), CAS (Cashews), COD (Codfish), EGG (Egg), HAZ (Hazelnuts), MIL (Milk), PEA (Peanuts), PEC (Pecans), PIS (Pistachios), SAL (Salmon), SES (Sesame Seed), SHR (Shrimp), SOY (Soybeans), WAL (Walnuts), WHE (Wheat) - EMEA-003397-PIP01-23 37
3.1.38. EMEA-003394-PIP01-23 37
3.1.39. Sodium hyaluronate / xylometazoline - EMEA-003387-PIP01-22 37
3.1.40. Salbutamol - EMEA-003398-PIP01-23 38
3.1.41. Tanimilast - EMEA-003393-PIP01-23 38
3.1.42. Complement factor B antisense oligonucleotide - EMEA-003396-PIP01-23 38
3.2. Discussions on Compliance Check 38
3.2.1. Dry aqueous extract of *Paullinia cupana* seed / liquid ethanolic extract 30 per cent (w/w) of *Allium cepa* fresh bulb and citrus limon fresh fruit / dry hydroethanolic extract of *Theobroma cacao* seed - EMEA-C1-001835-PIP01-15-M05 38
3.2.2. Efanesoctocog alfa - EMEA-C-002501-PIP01-18-M03 38
3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan 38
3.3.1. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alpha-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP01-19-M01 38
3.3.2. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alpha-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP03-20-M02 39
3.3.3. Landiolol (hydrochloride) - EMEA-001150-PIP02-13-M05 39
3.3.4. Treprostinil - EMEA-000207-PIP01-08-M08 39
3.3.5. Brodalumab - EMEA-001089-PIP02-13-M04 39

3.3.6. Ethinyl estradiol / dienogest - EMEA-002229-PIP02-21-M01 39
3.3.7. Denecimig - EMEA-002762-PIP02-20-M01 40
3.3.8. Lamivudine (3TC) / abacavir (ABC) / dolutegravir (DTG) - EMEA-001219-PIP01-11-M07 .. 40
3.3.9. Posaconazole - EMEA-000468-PIP02-12-M08 40
3.3.10. Regdanvimab - EMEA-002961-PIP01-21-M02 40
3.3.11. Sotrovimab - EMEA-002899-PIP01-20-M02 40
3.3.12. Tenofovir alafenamide / rilpivirine / emtricitabine - EMEA-001679-PIP01-14-M03 40
3.3.13. Efinaconazole - EMEA-001627-PIP01-14-M03 41
3.3.14. Ataluren - Orphan - EMEA-000115-PIP01-07-M13 41
3.3.15. Cenobamate - EMEA-002563-PIP02-19-M02 41
3.3.16. Odronextamab - Orphan - EMEA-003149-PIP01-21-M01 41
3.3.17. Bilastine - EMEA-000347-PIP02-16-M05 41
3.3.18. Ponesimod - EMEA-000798-PIP01-09-M04 41
3.3.19. Adsorbed modified allergen extract of a mixture of 50% *Dermatophagoides pteronyssinus* and 50% *Dermatophagoides farinae* - EMEA-000902-PIP01-10-M01 41

4. Nominations 42

4.1. List of submissions of applications with start of procedure 27 March 2023 for Nomination of Rapporteur and Peer reviewer 42

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver 42

4.3. Nominations for other activities 42

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction 42

5.1. New Scientific Advice 42

5.2. Final Scientific Advice (Reports and Scientific Advice letters) 43

6. Discussion on the applicability of class waivers 43

6.1. Discussions on the applicability of class waiver for products 43

6.1.1. Anti-human hemojuvelin (HJV) humanized monoclonal antibody - EMEA-09-2022 43
6.1.2. Non-steroidal small molecule androgen receptor pathway inhibitor - EMEA-11-2022 43
6.1.3. Elinzanetant - EMEA-01-2023 43

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 44

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver 44

7.1.1. Berotralstat - EMEA-002449-PIP02-18-M01 44
7.1.2. Vericiguat - EMEA-001636-PIP01-14-M03 44

8. Annual reports on deferrals 44
9. Organisational, regulatory and methodological matters 44
9.1. Mandate and organisation of the PDCO 44
9.1.1. PDCO membership 44
9.1.2. Vote by Proxy 45
9.1.3. Strategic Review and Learning Meeting (SRLM) - Uppsala, 7-8 June 2023 45
9.2. Coordination with EMA Scientific Committees or CMDh-v 45
9.2.1. Committee for Medicinal Products for Human Use (CHMP) 45
9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 45
9.3.1. Non-clinical Working Party: D30 Products identified 45
9.3.2. Formulation Working Group 46
9.3.3. Patients and Consumers Working Party (PCWP)/Healthcare Professionals Working Party (HCPWP) 46
9.3.4. Scientific Advice Working Party (SAWP) 46
9.4. Cooperation within the EU regulatory network 46
9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA) 46
9.4.2. PDCO / Health Technology Assessment (HTA) interaction 46
9.5. Cooperation with International Regulators 46
9.5.1. Paediatric Cluster Teleconference 46
9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee 47
9.7. PDCO work plan 47
9.8. Planning and reporting 47
9.8.1. EMA Business Pipeline activity and Horizon scanning 47
10. Any other business 47
10.1. COVID-19 update 47
10.2. WHO paediatric activities 47
10.3. Academic pilot for ATMPs 47
10.4. Upcoming Innovation Task Force (ITF) meetings 47
10.5. Concept paper on the revision of the Paediatric Addendum on pulmonary arterial hypertension guideline 48
10.6. Reflection paper on development of medicinal products to prevent and treat acute kidney injury 48
10.7. Draft Annex to CHMP guide on wording of the indication 48
11. Breakout sessions 48
11.1. Paediatric oncology 48
11.2. Neonatology 48
11.3. Vaccines 48

11.4. HIV 49

12. List of participants 50

13. Explanatory notes 53

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

The Chair opened the meeting by welcoming all participants. The meeting was held in-person with some members connected remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions taken at this meeting were made in the presence of a quorum of members. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair welcomed the new member(s) and alternate(s) and thanked the departing members/alternates for their contributions to the Committee.

1.2. Adoption of agenda

The agenda for 28-31 March 2023 meeting was adopted with amendments.

1.3. Adoption of the minutes

The minutes for 21-24 February 2023 meeting were adopted and will be published on the EMA website.

2. Opinions

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.1.1. 2-amino-5-(carbamylamino)pentanoic acid (L-citrulline) - EMEA-002612-PIP02-22

ASK Pharmaceuticals GmbH (ASK); Treatment of sickle cell disease

Day 120 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 2 years to less than 18 years of age, in the condition of treatment of sickle cell disease was adopted. The PDCO agreed on a waiver in a subset of children on the grounds of lack of significant therapeutic benefit.

2.1.2. Itolizumab - Orphan - EMEA-003208-PIP02-22

Biocon Pharma Malta-I Limited; Treatment of acute graft versus host disease

Day 120 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for patients from 28 days of age to less than 18 years of age, in the condition of treatment of acute graft versus host disease was adopted. The PDCO agreed on a waiver in a subset of children on the grounds of that the disease does not occur in the paediatric subset. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.3. Albaconazole - EMEA-003279-PIP01-22

Palau Pharma, S.L.; Treatment of acute vulvovaginal candidiasis

Day 120 opinion

Infectious Diseases

Summary of Committee discussion:

The PDCO agreed on a PIP for albaconazole for the treatment of acute vulvovaginal candidiasis in girls from menarche to less than 18 years of age. A waiver was granted for boys on the grounds that the disease or condition does not occur in this population and for pre-menarche girls on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments. The PIP includes two clinical trials in post-menarche girls (and adult women) as well as two modelling and simulation studies. The paediatric development is not deferred.

2.1.4. Opelconazole - EMEA-003249-PIP01-22

Treatment of bronchopulmonary aspergillosis / Treatment of invasive aspergillosis with indication limited to bronchopulmonary aspergillosis

Day 120 opinion

Infectious Diseases

Note: Withdrawal request received on 23 March 2023

2.1.5. A 2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting fused in sarcoma (FUS) pre-mRNA - EMEA-003024-PIP01-21

Ionis Pharmaceuticals; Treatment of amyotrophic lateral sclerosis (ALS)

Day 120 opinion

Neurology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for patients from 10 years to less than 18 years of age, in the condition of treatment of amyotrophic lateral sclerosis was adopted. The PDCO agreed on a waiver in a subset of children on the ground that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible. The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.6. Ocrelizumab - EMEA-000310-PIP05-22

Roche Registration GmbH; Treatment of multiple sclerosis

Day 120 opinion

Neurology

Summary of Committee discussion:

The PDCO re-discussed at Day 120, during the March 2023 plenary meeting, a PIP application for a new pharmaceutical form and route of administration of ocrelizumab for the treatment of multiple sclerosis.
The PDCO confirmed all conclusions reached at Day 90, took into consideration information provided between Day 90 and Day 120 and adopted a positive opinion at Day 120 on a paediatric investigation plan for ocrelizumab for the treatment of multiple sclerosis with a deferral and a waiver for children less than 10 years of age on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for these paediatric patients.

2.1.7. Pembrolizumab / favezelimab - EMEA-003104-PIP02-22

Merck Sharp & Dohme (Europe) Inc.; Treatment of Hodgkin lymphoma

Day 120 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children and adolescents from 3 years to less than years of age, in the condition of treatment of Hodgkin lymphoma (HL) was adopted. The PDCO agreed on a waiver in a subset of children on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.8. Pembrolizumab / vibostolimab - EMEA-003063-PIP02-22

Merck Sharp & Dohme (Europe) Inc.; Treatment of Hodgkin lymphoma

Day 120 opinion

Oncology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children and adolescents from 3 years to less than years of age, in the condition of treatment of Hodgkin lymphoma (HL) was adopted. The PDCO agreed on a waiver in a subset of children on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s). The PDCO granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.9. Aticaprant - EMEA-003251-PIP01-22

Janssen-Cilag International N.V.; Treatment of major depressive disorder

Day 120 opinion

Psychiatry

Summary of Committee discussion:

In their written response, the applicant addressed the remaining issues raised by the Committee. Based on the assessment of this application and the additional information provided by the applicant, a positive opinion for the PIP for the proposed medicine for children from 7 to less than 18 years of age, in the condition of treatment of major depressive disorder was adopted by consensus. The PDCO also agreed on a waiver in a subset of children on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset, and granted a deferral for one or more measures contained in the paediatric investigation plan.

2.1.10. Atrasentan - Orphan - EMEA-001666-PIP02-21

Chinook Therapeutics, Inc.; Treatment of IgA nephropathy

Day 120 opinion

Uro-nephrology

Summary of Committee discussion:

The PDCO agreed on a PIP for atrasentan for the treatment of IgA nephropathy in children from 2 years of age. A waiver was granted for children below 2 years of age based on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible. In addition to the film-coated tablet developed for adult use, the applicant is required to develop an age-appropriate oral formulation. Furthermore, the PIP includes a non-comparative trial to evaluate pharmacokinetics, safety and efficacy of atrasentan in subjects from 2 years to less than 18 years of age with IgA nephropathy, as well as a modelling and simulation study, which are both part of an extrapolation plan. The completion of the paediatric programme is deferred.

2.1.11. Atorvastatin / ezetimibe - EMEA-003373-PIP01-22

Pharmaplot PC; Treatment of hypercholesterolaemia

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The PDCO's view expressed at Day 30 was endorsed. Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for atorvastatin / ezetimibe for all subsets of the paediatric population (birth to less than 18 years of age) in the condition of treatment of hypercholesterolaemia on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.12. Ramipril / indapamide - EMEA-003372-PIP01-22

Zakłady Farmaceutyczne Polpharma S.A.; Treatment of hypertension

Day 60 opinion

Cardiovascular Diseases

Summary of Committee discussion:

The PDCO's view expressed at Day 30 was endorsed.
Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for ramipril / indapamide for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypertension on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2.1.13. Nipocalimab - Orphan - EMEA-002559-PIP07-22

Janssen-Cilag International NV; Treatment of Sjögren's syndrome

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for nipocalimab for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of Sjögren's syndrome on the grounds of lack of safety for children from birth to less than 2 years of age and the grounds of lack of significant therapeutic benefit for children from 2 years to less than 18 years of age.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.14. Adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene (LY3884963) - Orphan - EMEA-003374-PIP01-22

Prevail Therapeutics, a Wholly-Owned Subsidiary of Eli Lilly and Company; Treatment of frontotemporal dementia

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for adeno-associated viral vector serotype 9 expressing codon-optimized human GRN gene (LY3884963) for all subsets of the paediatric population (from birth to 18 years of age) in the condition of treatment of frontotemporal dementia.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.15. 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro- 2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop- 2-en-1-one adipate - EMEA-003364-PIP02-22

Roche Registration GmbH; Treatment of non-small cell lung cancer

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for the proposed medicine for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of treatment of non-small cell lung cancer on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.16. N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride - Orphan - EMEA-003371-PIP01-22

Relay Therapeutics Inc.; Treatment of cholangiocarcinoma

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the March 2023 plenary meeting, a request for a product-specific waiver for N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d] pyrimidin-6-yl)phenyl)methacrylamide hydrochloride for the treatment of cholangiocarcinoma on the grounds that the disease does not occur in paediatric patients.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of cholangiocarcinoma" on the grounds that the disease occurs only in adult populations.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.

2.1.17. Palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20) / Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20) / Palmitoyl-KSS-GQAEPDRAHYNIVTF (HPV-16 E7 43-57) / Palmitoyl-KSS-KKLLMGTLGIVCPICSQKP(HPV-16 E7 82-98) / Palmitoyl-KSS-LLMGTLGIV (HPV-16 E7 82-90) /Palmitoyl-KSS-ELQTTIHDIILECVYCKQQLL

PDS Biotechnology Corp.; Treatment of human papillomavirus (HPV) type 16 positive malignancies

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the March 2023 plenary meeting, a request for a product-specific waiver for [(2R)-2,3-bis[[(Z)-octadec-9-enoyl]oxy]propyl]-trimethylazanium chloride (R-DOTAP chloride) / Palmitoyl-KSS-MHGDTPTLHEYMLDLQPETT (HPV-16 E7 1-20) / Palmitoyl-KSS-YMLDLQPETT (HPV-16 E7 11-20) / Palmitoyl-KSS-GQAEPDRAHYNIVTF (HPV-16 E7 43-57) / Palmitoyl-KSS-KKLLMGTLGIVCPICSQKP(HPV-16 E7 82-98) / Palmitoyl-KSS-LLMGTLGIV (HPV-16 E7 82-90) / Palmitoyl-KSS-ELQTTIHDIILECVYCKQQLL (HPV-16 E6 25-45) for the treatment of recurrent metastatic cancers associated with HPV16 infection including head and neck, anal, cervical, vulvar, vaginal and penile squamous cell carcinomas on the grounds that the disease does not occur in paediatric patients.
The PDCO confirmed all conclusions reached at Day 30 and adopted a positive opinion at Day 60 on a product specific waiver for this product for all subsets of the paediatric population (from birth to less than 18 years of age) in the condition of "treatment of human papillomavirus (HPV) type 16 positive malignancies" on the grounds that the disease occurs only in adult populations.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.
The applicant agreed for the waiver to be extended to all pharmaceutical forms and all routes of administration.

2.1.18. Recombinant humanised monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1κ) directed against integrin alpha V beta 8 produced in Chinese hamster ovary (CHO) cells - EMEA-003376-PIP01-22

Pfizer Europa MA EEIG; Treatment of head and neck squamous cell carcinoma (HNSCC) / Treatment of renal cell carcinoma (RCC)

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for recombinant humanised monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1κ) directed against integrin αvβ8 produced in Chinese hamster ovary (CHO) cells for all subsets of the paediatric population

(birth to less than 18 years of age) in the conditions of conditions of renal cell malignancies treatment of head and neck squamous cell carcinoma based on the ground of lack of significant therapeutic benefit.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.19. Pitavastatin / ezetimibe - EMEA-003390-PIP01-23

Verisfield Single Member S.A.; Treatment of hypercholesterolaemia

Day 30 opinion

Cardiovascular Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for pitavastatin / ezetimibe for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of hypercholesterolaemia.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.20. Thiocolchicoside / diclofenac - EMEA-003339-PIP02-23

Verisfield Single Member S.A.; Treatment of pain

Day 30 opinion

Pain

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The condition proposed by the applicant is considered too narrow though, as the grounds for the waiver are applicable to all pain-related indications. The PDCO therefore recommended granting a waiver for thiocolchicoside / diclofenac for all subsets of the paediatric population (0 to 18 years of age) in the condition of treatment of pain.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.1.21. Isopropyl alcohol / chlorhexidine (digluconate) - EMEA-001338-PIP02-23

Ecolab Deutschland GmbH; Prevention of infections prior to invasive procedures

Day 30 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the assessment of this application and further discussions at the Paediatric Committee, the PDCO agreed with the applicant's request for a waiver. The PDCO recommended granting a waiver for isopropyl alcohol / chlorhexidine (digluconate) for all subsets of the paediatric population (0 to 18 years of age) in the condition of prevention of infections prior to invasive procedures.
The PDCO emphasised that the granting of a waiver for the condition mentioned above should not prevent the applicant from considering a development in the paediatric population in indications where there is a paediatric need. In principle according to the Paediatric Regulation, incentives for the development for use in the paediatric population are available even if a waiver has been granted in another condition.

2.2. Opinions on Compliance Check

2.2.1. Birch bark extract - EMEA-C-001299-PIP03-17-M01

Amryt Pharmaceuticals DAC; Treatment of epidermolysis bullosa

Day 60 opinion

Action: For adoption

Dermatology

Note: Withdrawal request received on 8 March 2023

2.2.2. Eltrombopag - EMEA-C-000170-PIP03-13-M04

Novartis Europharm Limited; Treatment of aplastic anaemia

Day 60 opinion

Action: For adoption

Haematology-Hemostaseology

Note: Withdrawal request received on 16 March 2023

2.2.3. Recombinant human A disintegrin and metalloprotease with thrombospondin type-1 motifs 13 - EMEA-C1-001160-PIP01-11-M03

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of thrombotic thrombocytopenic purpura

Day 60 letter

Haematology-Hemostaseology

Summary of Committee discussion:

The PDCO discussed the completed study(ies) and considered that these are compliant with the latest Agency's Decision (P/0489/2022) of 2 December 2022.
The PDCO finalised this partially completed compliance procedure on 31 March 2023.

2.2.4. Entrectinib - EMEA-C-002096-PIP01-16-M03

Roche Registration GmbH; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedure EMEA-C1-002096-PIP01-16.
The PDCO adopted on 31 March 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0351/2021) of 8 September 2021.

2.2.5. Larotrectinib - EMEA-C-001971-PIP02-16-M04

Bayer AG; Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:
- EMEA-C1-001971-PIP02-16-M01.

The PDCO adopted on 31 March 2023 an opinion confirming the compliance of all studies in the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0487/2021) of 3 December 2021.

2.2.6. Crizotinib - EMEA-C-001493-PIP03-18-M01

Pfizer Europe MA EEIG; Treatment of anaplastic large cell lymphoma

Day 30 opinion

Oncology

Summary of Committee discussion:

The PDCO took note of outcomes of preceding partial compliance check procedures:
- EMEA-C2-001493-PIP03-18-M01.

The PDCO adopted on 31 March 2023 an opinion confirming the compliance of all studies in

the agreed paediatric investigation plan as set out in the latest Agency's Decision (P/0036/2021) of 27 January 2021.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.3.1. Tralokinumab - EMEA-001900-PIP02-17-M07

LEO Pharma A/S; Treatment of atopic dermatitis

Day 60 opinion

Dermatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0096/2022 of 11 March 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.2. Dasiglucagon - EMEA-002233-PIP01-17-M02

Zealand Pharma A/S; Treatment of hypoglycaemia

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes in study timelines could be accepted. The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency´s latest decision (P/0393/2021 of 8 September 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.3. Elosulfase alfa - Orphan - EMEA-000973-PIP01-10-M04

BioMarin International Limited; Treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome)

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

The PDCO re-discussed at Day 60, during the March 2023 plenary meeting, a request for modification for elosulfase alfa for the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome). The applicant requested to shorten the follow-up duration of a

clinical study.
Based on the review of the documentation submitted by the applicant for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be acceptable. Therefore, the PDCO adopted a positive opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0055/2015 of 30 March 2015). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.4. Migalastat (hydrochloride) - Orphan - EMEA-001194-PIP01-11-M06

Amicus Therapeutics Europe Limited; Treatment of Fabry disease

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The modification involved a change in the development of the pharmaceutical form and changes in the design of clinical Study 4.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0126/2022 of 13 April 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.5. Romosozumab - EMEA-001075-PIP04-15-M06

UCB Pharma S.A.; Treatment of osteoporosis

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0551/2021 of 31 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.6. Tolvaptan - EMEA-001231-PIP02-13-M10

Otsuka Pharmaceutical Netherlands B.V.; Treatment of polycystic kidney disease / Treatment of dilutional hyponatraemia

Day 60 opinion

Endocrinology-Gynaecology-Fertility-Metabolism / Uro-nephrology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification involved changes to initiation dates of clinical studies.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0157/2022 of 13 May 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.7. Guselkumab - EMEA-001523-PIP04-19-M02

Janssen-Cilag International NV; Treatment of ulcerative colitis

Day 60 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that some of the proposed changes could be accepted. PDCO supported the inclusion of a double-blind maintenance phase in place of the open-label maintenance phase in Study 1, but also to maintain the secondary endpoint endoscopic healing (Mayo endoscopic subscore) at week 12 at this stage as recommended in the respective guideline.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0399/2022 of 9 September 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.8. Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain - EMEA-002942-PIP02-20-M01

Boehringer Ingelheim International GmbH; Treatment of obesity

Day 60 opinion

Gastroenterology-Hepatology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. Within this modification elements of Study 1 (randomised, double blind, parallel group, placebo-controlled study in paediatric patients from 6 years to less than 18 years of age with obesity or overweight grouped by pubertal stage to establish safety, efficacy, and pharmacokinetics) were modified.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0173/2022 of 13 May 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.9. Valoctocogene roxaparvovec - Orphan - EMEA-002427-PIP01-18-M02

BioMarin International Limited; Treatment of haemophilia A

Day 60 opinion

Haematology-Hemostaseology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification involves delaying the completion of the clinical studies by 4 years.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0148/2021 of 16 April 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.10. Anifrolumab - EMEA-001435-PIP02-16-M02

AstraZeneca AB; Treatment of systemic lupus erythematosus

Day 60 opinion

Immunology-Rheumatology-Transplantation

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modifications involved changes to clinical and modelling & simulation studies and delaying the completion of the paediatric investigation plan by almost 3 years.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0239/2020 of 16 June 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.11. Upadacitinib - EMEA-001741-PIP04-17-M04

AbbVie Ltd; Treatment of atopic dermatitis

Day 60 opinion

Immunology-Rheumatology-Transplantation / Dermatology

Note: Withdrawal request received on 30 March 2023

2.3.12. Gepotidacin - EMEA-002443-PIP01-18-M02

GlaxoSmithKline Trading Services Limited; Treatment of uncomplicated urinary tract infections

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as

set in the Agency's latest decision (P/0444/2022 of 28 October 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.13. Maribavir - Orphan - EMEA-000353-PIP02-16-M03

Takeda Pharmaceuticals International AG Ireland Branch; Treatment of cytomegalovirus (CMV) infection

Day 60 opinion

Infectious Diseases

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The change involved a delay of the PIP completion, and a shift of timelines of Studies 6, 7 and 8.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0422/2022 of 28 October 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.14. Efgartigimod alfa - Orphan - EMEA-002597-PIP05-21-M01

argenx BV; Treatment of myasthenia gravis

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0392/2021 of 8 September 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.15. Lasmiditan - EMEA-002166-PIP01-17-M07

Eli Lilly and Company Limited; Treatment of migraine headaches

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0291/2022 of 11 August 2022).

The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.16. Vatiquinone - Orphan - EMEA-001238-PIP03-21-M01

PTC Therapeutics International; Treatment of Friedreich's ataxia

Day 60 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification involved changes to a clinical study (Study 3).
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0543/2021 of 31 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.17. Binimetinib - EMEA-001454-PIP03-15-M03

Pierre Fabre Médicament; Treatment of melanoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0488/2022 of 2 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.18. Encorafenib - EMEA-001588-PIP01-13-M03

Pierre Fabre Médicament; Treatment of melanoma

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0487/2022 of 2 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.19. Isatuximab - EMEA-002205-PIP01-17-M04

Sanofi-Aventis Recherche & Développement; Treatment of malignant neoplasms of the haematopoietic and lymphoid tissue

Day 60 opinion

Oncology

Summary of Committee discussion:

The PDCO took note of the clarifications provided by the applicant after D30.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes consisting of the deletion of Study 3 (open-label, randomised controlled trial to evaluate the safety and efficacy of isatuximab used in combination with chemotherapy compared to chemotherapy in children from 28 days to less than 18 years of age with relapsed/refractory B or T acute lymphoblastic leukaemia or acute myeloid leukaemia in first or second relapse. The population to be included in the study is to be determined according to the results of Study 2) and Study 4 (open-label, randomised controlled trial to evaluate the efficacy and safety of isatuximab used in combination with chemotherapy compared to chemotherapy in children from 28 days to less than 18 years of age with newly diagnosed B or T acute lymphoblastic leukaemia or newly diagnosed acute myeloid leukaemia. The population to be included in the study is to be determined according to the results of Study 3) from the PIP study could be accepted. In view of the deletion of these studies, the date of completion of the PIP was anticipated.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0494/2022 of 2 December 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.20. Repotrectinib - EMEA-002635-PIP02-21-M01

Bristol-Myers Squibb Pharma EEIG; Treatment of all conditions included in the category of malignant neoplasms (except haematopoietic neoplasms)

Day 60 opinion

Oncology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0542/2021 of 31 December 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.21. Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LVV, encoding for the human α-L-iduronidase (IDUA) gene - Orphan - EMEA-003001-PIP01-21-M01

Orchard Therapeutics (Netherlands) B.V.; Treatment of mucopolysaccharidosis type I,

Hurler syndrome

Day 60 opinion

Other

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. Within this modification the applicant requested to update the study design for Study 2.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0105/2022 of 13 April 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.22. Iptacopan - Orphan - EMEA-002705-PIP01-19-M01

Novartis Europharm Limited; Treatment of C3 glomerulopathy

Day 60 opinion

Other

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes in Study 4 and the proposed changes in study timelines could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0417/2020 of 23 October 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.23. Meloxicam / bupivacaine - EMEA-002246-PIP01-17-M03

Heron Therapeutics B.V.; Treatment of acute postoperative pain

Day 60 opinion

Pain

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted including updating the pharmaceutical form and route of administration, some modifications to the non-clinical studies and a clinical study as well as the postponement of the PIP timelines.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0182/2021 of 10 May 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.24. Benralizumab - EMEA-001214-PIP09-21-M01

AstraZeneca AB; Treatment of eosinophilic granulomatosis with polyangiitis (EGPA)

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0225/2022 of 8 July 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.25. Sodium chloride / idrevloride - Orphan - EMEA-002935-PIP01-20-M03

Parion Sciences, Inc.; Treatment of primary ciliary dyskinesia (PCD)

Day 60 opinion

Pneumology - Allergology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0206/2022 of 10 June 2022). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.
The revised PIP separates the development in children above 12 years of age from that in younger children (from 2 to less than 12 years of age) into two studies, instead of a single study in children from 2 years to less than 18 years of age. This change is expected to streamline the development plan for children 12 years of age into a single study, in which the clinical development features unique to the younger subjects can be more efficiently implemented at paediatric pulmonary centres.
The study in adolescents (12 to less than 18 years of age) will be a randomised controlled three arm study of active treatment, placebo, and hypertonic saline solution, and the study below 12 years of age will consist of an open label part followed by a placebo controlled part.
The PIP now contains three studies, the first one a short course of treatment (28 days) in adolescents; the second a 48-weeks study in children from 2 to less than 12 years of age, and the third study in adolescents from 12 to less than 18 years of age. Chronologically the study in adolescent will conclude before the one in children from 2 to less than 12 years of age. There is no deferral in the PIP.

2.3.26. Finerenone - EMEA-001623-PIP01-14-M06

Bayer AG; Treatment of chronic kidney disease

Day 60 opinion

Uro-nephrology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification involved a review of the quality-related study (Study 1).
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0434/2022 of 28 October 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.27. Sparsentan - Orphan - EMEA-001984-PIP02-20-M01

Vifor (International) AG; Treatment of focal segmental glomerulosclerosis

Day 60 opinion

Uro-nephrology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed delay for the completion of Study 2 and PIP completion could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0021/2021 of 27 January 2021).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.28. Cholera vaccine, recombinant, live, oral (strain CVD 103-HgR) - EMEA-001490-PIP01-13-M04

Emergent Netherlands B.V.; Treatment of cholera disease caused by *Vibrio cholerae* serogroup O1

Day 60 opinion

Vaccines

Summary of Committee discussion:

In the written response, the applicant addressed the remaining issues raised by the Committee.
Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0509/2020 of 22 December 2020).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.29. Acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid) - Orphan - EMEA-002796-PIP01-20-M01

IntraBio Ltd.; Treatment of Niemann-Pick disease type C

Day 30 opinion

Neurology

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification involved delaying the completion of clinical Study 4 by 6 months and by including the completion of this study in the deferral.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0043/2022 of 10 February 2022).
The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.30. Cariprazine hydrochloride - EMEA-001652-PIP01-14-M05

Gedeon Richter Plc.; Treatment of schizophrenia

Day 30 opinion

Psychiatry

Summary of Committee discussion:

Based on the review of the rationale submitted by the application for modifying the agreed paediatric investigation plan, the PDCO considered that the proposed changes could be accepted. The modification added a new pharmaceutical form to the agreed PIP.
The PDCO therefore adopted a favourable opinion on the modification of the agreed PIP as set in the Agency's latest decision (P/0105/2021 of 17 March 2021). The new PDCO opinion on the modified agreed PIP supersedes the previous PDCO opinion.

2.3.31. Elasomeran / imelasomeran, elasomeran / davesomeran, elasomeran - EMEA-002893-PIP01-20-M03

Moderna Biotech Spain, S.L.; Prevention of coronavirus disease 2019 (COVID-19)

Day 30 opinion

Vaccines

Summary of Committee discussion:

The applicant submitted a modification to add the mRNA vaccine targeting BA.4/BA.5 (davesomeran) to the PIP as part of a bivalent vaccine with elasomeran, the original Spikevax vaccine. The PDCO considered the modification acceptable and adopted a positive opinion for elasomeran / imelasomeran, elasomeran / davesomeran, elasomeran for the prevention of COVID-19 in children from 12 weeks of age to less than 18 years of age.

2.4. Opinions on Re-examinations

No item

2.5. Opinions on Review of Granted Waivers

No item

2.6. Finalisation and adoption of Opinions

No item

2.7. Partial Compliance Checks completed by EMA

The following partial compliance checks have been identified by the PME coordinator and PDCO rapporteur as not needing to be referred to the PDCO for discussion. The PDCO has been informed in writing.

2.7.1. Lacosamide - EMEA-C2-000402-PIP03-17-M06

UCB Pharma S.A.; Treatment of generalised epilepsy and epileptic syndromes

Day 30 letter

Neurology

3. Discussion of applications

Some information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.1.1. Insulin human (rDNA) - EMEA-003194-PIP02-22

Treatment of type 2 diabetes mellitus

Day 90 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.2. Crofelemer- Orphan - EMEA-003296-PIP01-22

Napo Therapeutics S.p.A.; Treatment of short bowel syndrome

Day 90 discussion

Gastroenterology-Hepatology

3.1.3. Efgartigimod alfa - EMEA-002597-PIP08-22

Treatment of dermatomyositis / Treatment of polymyositis (including antisynthetase syndrome) / Treatment of immune-mediated necrotising myopathy

Day 90 discussion

Immunology-Rheumatology-Transplantation

3.1.4. Asunercept - Orphan - EMEA-003201-PIP01-22

Apogenix AG; Treatment of coronavirus disease 2019 (COVID-19)

Day 90 discussion

Infectious Diseases

3.1.5. Fosmanogepix - Orphan - EMEA-003280-PIP01-22

Pfizer Europe MA EEIG; Treatment of invasive fungal infections

Day 90 discussion

Infectious Diseases

3.1.6. RNA replicase inhibitor - EMEA-003306-PIP01-22

Treatment of coronavirus disease 2019 (COVID-19)

Day 90 discussion

Infectious Diseases

3.1.7. Humanised VHH-type bispecific antibody against complement component 5 and serum albumin - EMEA-003302-PIP01-22

Treatment of acetylcholine receptor-antibody positive generalised myasthenia gravis

Day 90 discussion

Neurology

3.1.8. Adult differentiated autologous T-cells from peripheral blood, expanded and transduced with a lentivirus to express a chimeric antigen receptor with anti-CD19 specificity (A3B1) conjugated with the co-stimulatory regions 4-1BB and CD3z - EMEA-003264-PIP01-22

Treatment of B-lymphoblastic leukaemia/lymphoma

Day 90 discussion

Oncology

3.1.9. Live attenuated respiratory syncytial virus (RSV) - EMEA-003277-PIP01-22

Prevention of respiratory syncytial virus (RSV) disease

Day 90 discussion

Vaccines

3.1.10. Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation - EMEA-003309-PIP01-22

Prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV)

Day 90 discussion

Vaccines

3.1.11. Upadacitinib - EMEA-001741-PIP08-22

Treatment of hidradenitis suppurativa

Day 60 discussion

Dermatology

3.1.12. *Escherichia coli*, expressing high affinity phenylalanine transporter, modified phenylalanine ammonia lyase and L-amino acid deaminase - EMEA-003381-PIP01-22

Treatment of hyperphenylalaninemia

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.13. Leuprorelin - EMEA-003354-PIP01-22

Treatment of central (gonadotropin-dependent) precocious puberty

Day 60 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.14. Cemdisiran - Orphan - EMEA-003237-PIP02-22

Regeneron Ireland DAC; Treatment of paroxysmal nocturnal haemoglobinuria

Day 60 discussion

Haematology-Hemostaseology

3.1.15. Pozelimab - EMEA-003238-PIP02-22

Treatment of paroxysmal nocturnal haemoglobinuria

Day 60 discussion

Haematology-Hemostaseology

3.1.16. Axatilimab - EMEA-003385-PIP01-22

Treatment of chronic graft-versus-host-disease

Day 60 discussion

Immunology-Rheumatology-Transplantation

3.1.17. Inebilizumab - EMEA-001911-PIP02-22

Treatment of generalised myasthenia gravis

Day 60 discussion

Neurology

3.1.18. Cobolimab - EMEA-003273-PIP02-22

Treatment of all conditions included in the category of malignant neoplasms including lymphoma (except lung cancers and hematopoietic malignancies)

Day 60 discussion

Oncology

3.1.19. Pembrolizumab / vibostolimab - EMEA-003063-PIP03-22

Treatment of melanoma

Day 60 discussion

Oncology

3.1.20. Taldefgrobep alfa - EMEA-003386-PIP01-22

Treatment of spinal muscular atrophy

Day 60 discussion

Other

3.1.21. EMEA-003319-PIP04-22

Treatment of borderline personality disorder (BPD)

Day 60 discussion

Psychiatry

3.1.22. *Neisseria meningitidis* group A, C, W, Y polysaccharide conjugated to tetanus toxoid carrier protein, and *Neisseria meningitidis* serogroup B proteins and protein-based active substance - EMEA-003379-PIP01-22

Prevention of meningococcal disease

Day 60 discussion

Vaccines

3.1.23. Recombinant human monoclonal antibody to insulin receptor - Orphan - EMEA-002813-PIP01-23

Rezolute (Bio) Ireland Limited; Treatment of hyperinsulinaemic hypoglycaemia

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.1.24. Inebilizumab - EMEA-001911-PIP03-23

Treatment of immunoglobulin G4-related disease (IgG4-RD)

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.25. Upadacitinib - EMEA-001741-PIP09-23

Treatment of systemic lupus erythematosus

Day 30 discussion

Immunology-Rheumatology-Transplantation

3.1.26. Iodine (131I) apamistamab - Orphan - EMEA-003395-PIP01-23

Immedica Pharma AB; Conditioning treatment prior to haematopoietic stem cell transplantation (HSCT) in malignant neoplasms of haematopoietic and lymphoid tissue

Day 30 discussion

Immunology-Rheumatology-Transplantation / Oncology

3.1.27. Haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R,4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate (ECT-001-CB) - Orphan - EMEA-003025-PIP03-23

ExCellThera; Treatment in allogeneic haematopoietic stem cell transplantation

Day 30 discussion

Immunology-Rheumatology-Transplantation / Oncology / Haematology-Hemostaseology

3.1.28. Amphotericin B - Orphan - EMEA-003391-PIP01-23

Matinas BioPharma Holdings Inc.; Treatment of cryptococcosis

Day 30 discussion

Infectious Diseases

3.1.29. Broadly neutralising anti-HIV human monoclonal antibody - EMEA-003392-PIP01-23

Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.1.30. Carbidopa / levodopa - EMEA-003384-PIP02-23

Treatment of Parkinson's disease

Day 30 discussion

Neurology

3.1.31. Deutetrabenazine - EMEA-002052-PIP02-23

Treatment of tardive dyskinesia

Day 30 discussion

Neurology

3.1.32. Inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1) - EMEA-003383-PIP02-23

Treatment of amyotrophic lateral sclerosis

Day 30 discussion

Neurology

3.1.33. Belzutifan - Orphan - EMEA-002619-PIP02-23

Merck, Sharp & Dohme (Europe) Inc; Treatment of von Hippel-Lindau disease (except von Hippel-Lindau disease associated renal cell carcinoma) / Treatment of neuroendocrine tumours

Day 30 discussion

Oncology

3.1.34. EMEA-003260-PIP02-23

Treatment of biliary tract cancer

Day 30 discussion

Oncology

3.1.35. Dordaviprone - Orphan - EMEA-003389-PIP01-23

Chimerix IRL Limited; Treatment of high-grade glioma

Day 30 discussion

Oncology

3.1.36. (S)-lactic acid - EMEA-003247-PIP02-23

Treatment of degenerative disc disease

Day 30 discussion

Other

3.1.37. ALM (Almonds), CAS (Cashews), COD (Codfish), EGG (Egg), HAZ (Hazelnuts), MIL (Milk), PEA (Peanuts), PEC (Pecans), PIS (Pistachios), SAL (Salmon), SES (Sesame Seed), SHR (Shrimp), SOY (Soybeans), WAL (Walnuts), WHE (Wheat) - EMEA-003397-PIP01-23

Treatment of food allergy

Day 30 discussion

Other

3.1.38. EMEA-003394-PIP01-23

Treatment of Duchenne/Becker muscular dystrophy

Day 30 discussion

Other / Neurology

3.1.39. Sodium hyaluronate / xylometazoline - EMEA-003387-PIP01-22

Treatment of acute viral rhinosinusitis

Day 30 discussion

Oto-rhino-laryngology

3.1.40. Salbutamol - EMEA-003398-PIP01-23

Treatment of asthma

Day 30 discussion

Pneumology - Allergology

3.1.41. Tanimilast - EMEA-003393-PIP01-23

Treatment of asthma

Day 30 discussion

Pneumology - Allergology

3.1.42. Complement factor B antisense oligonucleotide - EMEA-003396-PIP01-23

Treatment of glomerulonephritis and nephrotic syndrome / Treatment of primary IgAN

Day 30 discussion

Uro-nephrology

3.2. Discussions on Compliance Check

The following compliance checks have been identified for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

3.2.1. Dry aqueous extract of *Paullinia cupana* seed / liquid ethanolic extract 30 per cent (w/w) of *Allium cepa* fresh bulb and citrus limon fresh fruit / dry hydroethanolic extract of *Theobroma cacao* seed - EMEA-C1-001835-PIP01-15-M05

LEGACY HEALTHCARE (FRANCE)SAS; Treatment of alopecia

Day 30 discussion

Dermatology

3.2.2. Efanesoctocog alfa - EMEA-C-002501-PIP01-18-M03

Swedish Orphan Biovitrium; Treatment of haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

3.3.1. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alpha-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-

acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP01-19-M01

Dr. Franz Köhler Chemie GmbH; Cardioplegia

Day 30 discussion

Cardiovascular Diseases

3.3.2. 3,4-Dimethoxy-N-methylbenzohydroxamic acid / deferoxamine mesylate / alpha-ketoglutaric acid / arginine / alanine / glycine / aspartic acid / tryptophan / N-acetyl-histidine (monohydrate) / histidine / calcium chloride (dihydrate) / magnesium chloride (hexahydrate) / potassium chloride / sodium chloride - EMEA-002735-PIP03-20-M02

Dr. Franz Köhler Chemie GmbH; Heart transplantation

Day 30 discussion

Cardiovascular Diseases

3.3.3. Landiolol (hydrochloride) - EMEA-001150-PIP02-13-M05

AOP Orphan Pharmaceuticals GmbH; Treatment of supraventricular arrythmias

Day 30 discussion

Cardiovascular Diseases

3.3.4. Treprostinil - EMEA-000207-PIP01-08-M08

Ferrer Internacional, S.A.; Other secondary hypertension / Primary pulmonary hypertension

Day 30 discussion

Cardiovascular Diseases

3.3.5. Brodalumab - EMEA-001089-PIP02-13-M04

LEO Pharma A/S; Treatment of psoriasis

Day 30 discussion

Dermatology

3.3.6. Ethinyl estradiol / dienogest - EMEA-002229-PIP02-21-M01

Chemo Research; Treatment of polycystic ovary syndrome

Day 30 discussion

Endocrinology-Gynaecology-Fertility-Metabolism

3.3.7. Denecimig - EMEA-002762-PIP02-20-M01

Novo Nordisk A/S; Treatment of haemophilia A

Day 30 discussion

Haematology-Hemostaseology

3.3.8. Lamivudine (3TC) / abacavir (ABC) / dolutegravir (DTG) - EMEA-001219-PIP01-11-M07

ViiV Healthcare UK Limited; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.9. Posaconazole - EMEA-000468-PIP02-12-M08

Merck Sharp & Dohme (Europe), Inc.; Prevention of invasive fungal infections / Treatment of invasive fungal infections

Day 30 discussion

Infectious Diseases

3.3.10. Regdanvimab - EMEA-002961-PIP01-21-M02

Celltrion Healthcare Hungary Kft.; Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.3.11. Sotrovimab - EMEA-002899-PIP01-20-M02

GlaxoSmithKline Trading Services Ltd; Treatment of coronavirus disease 2019 (COVID-19)

Day 30 discussion

Infectious Diseases

3.3.12. Tenofovir alafenamide / rilpivirine / emtricitabine - EMEA-001679-PIP01-14-M03

Gilead Sciences International Ltd.; Treatment of human immunodeficiency virus (HIV-1) infection

Day 30 discussion

Infectious Diseases

3.3.13. Efinaconazole - EMEA-001627-PIP01-14-M03

Almirall, S.A.; Treatment of onychomycosis

Day 30 discussion

Infectious Diseases / Dermatology

3.3.14. Ataluren - Orphan - EMEA-000115-PIP01-07-M13

PTC Therapeutics International, Limited; Treatment of dystrophinopathy

Day 30 discussion

Neurology

3.3.15. Cenobamate - EMEA-002563-PIP02-19-M02

Angelini Pharma S.p.A; Treatment of focal onset seizures / Treatment of primary generalised tonic clonic seizures

Day 30 discussion

Neurology

3.3.16. Odronextamab - Orphan - EMEA-003149-PIP01-21-M01

Regeneron Ireland DAC; Treatment of mature B cell malignancies

Day 30 discussion

Oncology

3.3.17. Bilastine - EMEA-000347-PIP02-16-M05

Faes Farma S.A.; Treatment of allergic conjunctivitis

Day 30 discussion

Ophthalmology

3.3.18. Ponesimod - EMEA-000798-PIP01-09-M04

Janssen-Cilag International NV; Treatment of multiple sclerosis

Day 30 discussion

Other / Neurology

3.3.19. Adsorbed modified allergen extract of a mixture of 50% *Dermatophagoides pteronyssinus* and 50% *Dermatophagoides farinae* - EMEA-000902-PIP01-10-M01

HAL Allergy BV; Treatment of allergic rhinitis/rhino-conjunctivitis

Day 30 discussion

Pneumology - Allergology

4. Nominations

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

4.1. List of submissions of applications with start of procedure 27 March 2023 for Nomination of Rapporteur and Peer reviewer

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

4.3. Nominations for other activities

Summary of Committee discussion:

The PDCO approved the lists of Rapporteurs and Peer Reviewers.

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Information related to this section cannot be disclosed at the present time as it is deemed to contain commercially confidential information.

5.1. New Scientific Advice

No item

5.2. Final Scientific Advice (Reports and Scientific Advice letters)

6. Discussion on the applicability of class waivers

6.1. Discussions on the applicability of class waiver for products

6.1.1. Anti-human hemojuvelin (HJV) humanized monoclonal antibody - EMEA-09-2022

Disc Medicine B.V.; The class of ribonucleotide reductase beta-2 inhibitor medicinal products, the class of primarily alkylating medicinal products and the class of immunomodulatory cytokine medicinal products for the treatment of myeloproliferative neoplasms / Treatment of anaemia in myelofibrosis

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indications was not confirmed. This was based on the consideration that the product does not belong to any of the classes of medicinal products included in the EMA Decision CW/0001/2015 for the treatment of myeloproliferative neoplasms, i.e., the class of ribonucleotide reductase beta-2 inhibitor medicinal products, the class of primarily alkylating medicinal products, the class of immunomodulatory cytokine medicinal products for the treatment of myeloproliferative neoplasms.

Other potential paediatric interests of this medicine suggested by PDCO: anaemia associated to high hepcidin levels, not only myelofibrosis but other diseases such as chronic diseases/anaemia of inflammation.

6.1.2. Non-steroidal small molecule androgen receptor pathway inhibitor - EMEA-11-2022

Merck Sharp & Dohme (Europe), Inc; The class of androgen receptor modulator, oestrogen receptor modulator, of growth and sex hormone as well as their releasing or inhibiting factors, and of sex hormone-metabolism modulator medicinal products for the treatment of prostate malignant neoplasms / Treatment of patients with metastatic castration-resistant prostate cancer

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indications was confirmed.

Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

6.1.3. Elinzanetant - EMEA-01-2023

Bayer AG; All classes of medicinal products for treatment of climacteric symptoms associated with decreased oestrogen levels, as occurring at menopause

Summary of Committee discussion:

The applicability of the class waiver as referred to in the Agency's Decision CW/0001/2015 to the planned therapeutic indications was not confirmed as the product does not belong to all classes of medicinal products for treatment of climacteric symptoms associated with decreased oestrogen levels, as occurring at menopause.

This was based on the consideration that the condition of the EMA Decision CW/0001/2015 refers specifically to symptoms related to decreased oestrogen levels due to menopause.

Other potential paediatric interests of this medicine suggested by PDCO: none identified at this stage.

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

7.1.1. Berotralstat - EMEA-002449-PIP02-18-M01

BioCryst Ireland Limited; Treatment of hereditary angioedema / Prevention of attacks in patients with hereditary angioedema

Summary of Committee discussion:

The planned indication has been confirmed to be within the agreed PIP condition.

7.1.2. Vericiguat - EMEA-001636-PIP01-14-M03

Bayer AG; Treatment of left ventricular failure

Summary of Committee discussion:

The planned indication has been confirmed to be within the agreed PIP condition.

8. Annual reports on deferrals

The members of the PDCO took note of the products listed in the Annex B.

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO membership

The Chair welcomed Sara Galluzzo as the new member for Italy, Greta Budukeviciute as the new alternate for Lithuania, Cinzia Ciceroni as the new alternate for Italy and David

Khan as the new alternate for Sweden.

The Chair thanked Silvijus Abramavicius as the alternate for Lithuania and Kristin Karlsson as the member for Sweden for their contribution.

The Chair announced that Sara Vennberg is the new member for Sweden, replacing Kristin Karlsson.

9.1.2. Vote by Proxy

None

9.1.3. Strategic Review and Learning Meeting (SRLM) - Uppsala, 7-8 June 2023

PDCO member: Sara Vennberg

Summary of Committee discussion:

Draft agenda of the next strategic review and learning meeting in Uppsala was shared with PDCO members.

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Summary of Committee discussion:

The list of PIP-related CHMP procedures starting in February 2023, was presented to the PDCO members.

Feedback on the ongoing CHMP procedures was provided to the Committee by the nominated PDCO experts.

An overview of discussions on PIP-related procedures, held by the CHMP in March 2023, was provided by one of CHMP / PDCO members.

Feedback on ongoing CHMP procedures was provided to the Committee by the PDCO

experts involved.

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Party: D30 Products identified

PDCO member: Karen van Malderen

Summary of Committee discussion:

The Vice-Chair of the Non-clinical Working Party (NcWP) identified the products which will require NcWP evaluation and discussion.

9.3.2. Formulation Working Group

PDCO member: Brian Aylward (*ad interim*)

Summary of Committee discussion:

The Chair of the Formulation Working Group (FWG) identified the products which will require FWG evaluation and discussion.

9.3.3. Patients and Consumers Working Party (PCWP)/Healthcare Professionals Working Party (HCPWP)

No item

9.3.4. Scientific Advice Working Party (SAWP)

Proposal for PDCO consultation of SAWP

Summary of Committee discussion:

The proposal includes a high-level process whereby the PDCO could seek input from the SAWP on specific issues during the assessment of a PIP (or modification).

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

No item

9.4.2. PDCO / Health Technology Assessment (HTA) interaction

Update on current initiatives

Summary of Committee discussion:

The Committee was informed about ongoing activities to increasing interactions with interested HTA bodies in PIP assessments.

9.5. Cooperation with International Regulators

9.5.1. Paediatric Cluster Teleconference

Summary of Committee discussion:

The March 2023 agenda of the cluster was shared with the PDCO members for information.

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

No item

9.7. PDCO work plan

No Item

9.8. Planning and reporting

9.8.1. EMA Business Pipeline activity and Horizon scanning

Q1/2023 Update of the Business Pipeline report for the human scientific committees

Summary of Committee discussion:

The business pipeline report for Q1/2023 was provided for information.

10. Any other business

10.1. COVID-19 update

Summary of Committee discussion:

Updates were provided to the PDCO on the current epidemiology of COVID-19 including the currently circulating SRS-CoV-2 variants, on emerging data on the clinical manifestations of the disease, and on the newest developments in relation to COVID-19 vaccines.

10.2. WHO paediatric activities

WHO experts: Marie Valentin, Martina Penazzato

Summary of Committee discussion:

Presentation on WHO paediatric activities was shared with PDCO members.

10.3. Academic pilot for ATMPs

Summary of Committee discussion:

The Committee was informed about the academic pilot that the EMA has recently started to help academic institutions developing advanced therapy medicinal products.

10.4. Upcoming Innovation Task Force (ITF) meetings

Summary of Committee discussion:

Three ITF meetings taking place in March and April 2023 were presented for information.

10.5. Concept paper on the revision of the Paediatric Addendum on pulmonary arterial hypertension guideline

Summary of Committee discussion:

The comments from the PDCO members regarding the concept paper on the revision of the Paediatric Addendum on pulmonary arterial hypertension guideline have been presented to the PDCO. No further comments followed during the plenary session. The concept paper with comments has been agreed.

10.6. Reflection paper on development of medicinal products to prevent and treat acute kidney injury

Summary of Committee discussion:

The PDCO was informed that the Committee for Medicinal Products for Human Use (CHMP) was drafting a reflection paper on the development of medicinal products to prevent acute kidney injury. A call was made for interested PDCO members to join the drafting group and to provide input for the paediatric section of the reflection paper.

10.7. Draft Annex to CHMP guide on wording of the indication

PDCO member: Siri Wang

Summary of Committee discussion:

PDCO member Siri Wang presented the draft Annex to CHMP guide on the wording of the indication. It was agreed that PDCO members could send comments on the draft to PDCO Secretariat in writing.

11. Breakout sessions

11.1. Paediatric oncology

Summary of Committee discussion:

The group discussed about the format of the Accelerate Paediatric Forums.

11.2. Neonatology

Summary of Committee discussion:

Organisational aspects for the revision of the neonatal Guideline.

11.3. Vaccines

Summary of Committee discussion:

The BOS was cancelled.

11.4. HIV

Summary of Committee discussion:

At the BOS members discussed on aspect relating to ongoing procedures of the HIV therapeutic area for discussion at the plenary.

The Chair thanked all participants and closed the meeting.

12. List of participants

List of participants including any restrictions with respect to involvement of members / alternates / experts following evaluation of declared interests for the 28-31 March 2023 meeting.

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Brian Aylward	Chair	Ireland	No interests declared	
Karl-Heinz Huemer	Member	Austria	No interests declared	
Marleen Renard	Member	Belgium	No participation in discussion, final deliberations and voting on:	2.3.30. Posaconazole - EMEA-000468-PIP02-12-M08
Karen Van Malderen	Alternate	Belgium	No interests declared	
Dimitar Roussinov	Member	Bulgaria	No restrictions applicable to this meeting	
Zena Gunther	Member	Cyprus	No interests declared	
Tereza Bazantova	Alternate	Czechia	No interests declared	
Nanna Borup Johansen	Member	Denmark	No interests declared	
Louisa Braun Exner	Alternate	Denmark	No interests declared	
Irja Lutsar	Member	Estonia	No interests declared	
Jana Lass	Alternate	Estonia	No interests declared	
Pauliina Lehtolainen-Dalkilic	Member	Finland	No interests declared	
Anne Paavola	Alternate	Finland	No interests declared	
Sylvie Benchetrit	Member (Vice-Chair)	France	No interests declared	
Dominique Ploin	Alternate	France	No interests declared	
Sabine Scherer	Member	Germany	No interests declared	
Yuansheng Sun	Alternate	Germany	No interests declared	
Eleni Katsomiti	Member	Greece	No interests declared	
Adrienn Horváth	Member	Hungary	No interests declared	
Sara Galluzzo	Member	Italy	No interests declared	
Cinzia Ciceroni	Alternate	Italy	No interests declared	
Dina Apele-Freimane	Member	Latvia	No restrictions applicable to this meeting	
Carola de Beaufort	Member	Luxembourg	No restrictions applicable to this meeting	
Olivier Moes	Alternate	Luxembourg	No interests declared	
Herbert	Alternate	Malta	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Lenicker				
Roderick Houwen	Member	Netherlands	No restrictions applicable to this meeting	
Maaike van Dartel	Alternate	Netherlands	No interests declared	
Siri Wang	Member	Norway	No interests declared	
Anette Solli Karlsen	Alternate	Norway	No interests declared	
Marek Migdal	Member	Poland	No restrictions applicable to this meeting	
Helena Fonseca	Member	Portugal	No interests declared	
Hugo Tavares	Alternate	Portugal	No interests declared	
Dana Gabriela Marin	Member (CHMP alternate)	Romania	No interests declared	
Peter Sisovsky	Member	Slovakia	No interests declared	
Peter Szitanyi	Alternate	Slovakia	No interests declared	
Stefan Grosek	Member	Slovenia	No interests declared	
Fernando de Andrés Trelles	Member	Spain	No interests declared	
Maria Jesus Fernández Cortizo	Alternate	Spain	No interests declared	
Sara Vennberg	Member	Sweden	No interests declared	
David Khan	Alternate	Sweden	No restrictions applicable to this meeting	
Johannes Taminiau	Member	Healthcare Professionals' Representative	No interests declared	
Fernando Cabanas	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Francesca Rocchi	Member	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jose Ignacio Malagon Calle	Alternate	Healthcare Professionals' Representative	No restrictions applicable to this meeting	
Jaroslav Sterba	Member	Patients' Organisation Representative	No restrictions applicable to this meeting	
Dimitrios Athanasiou	Member	Patients' Organisation Representative	No interests declared	
Tomasz Grybek	Member	Patients' Organisation Representative	No interests declared	
María Estela	Expert - via	Spain	No interests declared	

Name	Role	Member state or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Moreno Martín	telephone			
Celine Chu	Expert - via telephone	France	No interests declared	
Rune Kjeken	Expert - via telephone	Norway	No restrictions applicable to this meeting	
Marie Valentin	Invited speaker	WHO	Confidentiality agreement	
Martina Penazzato	Invited speaker	WHO	Confidentiality agreement	
Ann Marie Totterman	Expert - via telephone	Finland	No interests declared	
Anthony Nunn	Expert - via telephone	United Kingdom	No interests declared	
Sara Arenas-Lopez	Expert - via telephone	United Kingdom	No interests declared	
Olga Kholmanskikh	Expert - via telephone	Belgium	No interests declared	
Meeting run with support from relevant EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

13. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (*section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs*)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (*section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check*)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (*section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP*)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (*section 6 Discussion on the applicability of class waiver*)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (*section 8*)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/